Effect of intermittent interleukin-2 therapy on CD4 + T-cell counts following antiretroviral cessation in patients with HIV

AIDS

Volumn 26, Issue 6, 2012, Pages 711-720

  Lévy, Yves ^a,b,c   Thiébaut, Rodolphe ^a,d,e   Gougeon, Marie Lise ^f   Molina, Jean Michel ^g   Weiss, Laurence ^h   Girard, Pierre Marie ⁱ   Venet, Alain ^a   Morlat, Philippe ^a,e   Poirier, Béatrice ^f   Lascaux, Anne Sophie ^c   Boucherie, Céline ^a   Sereni, Daniel ^g   Rouzioux, Christine ^j   Viard, Jean Paul ^k   Lane, Cliff ^l   Delfraissy, Jean François ^m   Sereti, Irini ^l   Chêne, Geneviève ^a,d,e   Goujard, C ⁿ   Rancinan, C ⁿ   Taburet, A M ⁿ   Couffin Cadiergues, S ⁿ   Beumont, M ⁿ   Avettand Fenoel, V ⁿ   Bocquentin, M ⁿ   Jung, C ⁿ   Lacabaratz, C ⁿ   Rogge, L ⁿ   more..

^a INSERM   (France)

^b FACULTÉ DE MÉDECINE   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f INSTITUT PASTEUR   (France)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^h HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁱ HÔPITAL SAINT ANTOINE   (France)

^j HÔPITAL NECKER ENFANTS MALADES   (France)

^k HÔTEL DIEU   (France)

^l NATIONAL INSTITUTES OF HEALTH   (United States)

^m BICÊTRE HOSPITAL   (France)

ⁿ National Institutes of Health ^*

more..

Author keywords

antiretroviral therapy interruption; HIV; interleukin 2

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RECOMBINANT INTERLEUKIN 2; VIRUS DNA; VIRUS RNA;

ADULT; ARTICLE; ASTHENIA; CD4 LYMPHOCYTE COUNT; CLINICAL PROTOCOL; CONTROLLED STUDY; DEATH; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS CANDIDIASIS; FEMALE; FEVER; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; KAPLAN MEIER METHOD; LUNG CARCINOMA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; ANTIGENS, CD38; ANTIGENS, CD8; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84859101981     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283519214     Document Type: Article

References (32)

1. Levy Y, Capitant C, Houhou S, Carriere I, Viard JP, Goujard C, et al. Comparison ofsubcutaneous and intravenous interleukin- 2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group. Lancet 1999; 353:1923-1929. (Pubitemid 29255705)
2. Sereti I, Anthony KB, Martinez Wilson H, Lempicki R, Adelsberger J, Metcalf JA, et al. IL-2-induced CD4(+) T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood 2004; 104:775-780. (Pubitemid 38970572)
3. Levy Y, Durier C, Krzysiek R, Rabian C, Capitant C, Lascaux AS, et al. Effects ofinterleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial. AIDS 2003; 17:343-351. (Pubitemid 36223259)
4. Farel CE, Chaitt DG, Hahn BK, Tavel JA, Kovacs JA, Polis MA, et al. Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection. Blood 2004; 103:3282-3286. (Pubitemid 38525652)
5. Durier C, Capitant C, Lascaux AS, Goujard C, Oksenhendler E, Poizot-Martin I, et al. Long-term effects ofintermittent interleukin- 2 therapy in chronic HIV-infected patients (ANRS 048-079 Trials). AIDS 2007; 21:1887-1897. (Pubitemid 47329765)
6. Abrams D, Levy Y, Losso MH, Babiker A, Collins G, Cooper DA, et al. Interleukin-2 therapy inpatients with HIV infection. N Engl J Med 2009; 361:1548-1559.
7. Weiss L, Letimier FA, Carriere M, Maiella S, Donkova-Petrini V, Targat B, et al. In vivo expansion ofnaive and activated CD4+CD25+FOXP3+ regulatory T cell populations in interleukin- 2-treated HIV patients. Proc Nat Acad Sci USA 2010; 107:10632-10637.
8. Molina JM, Levy Y, Fournier I, Hamonic S, Bentata M, Beck-Wirth G, et al. Interleukin-2 before Antiretroviral Therapy in Patients with HIV Infection: A Randomized Trial (ANRS 119). J Infect Dis 2009; 200:206-215.
9. Tavel JA, Babiker A, Fox L, Gey D, Lopardo G, Markowitz N, et al. Effects ofintermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study. PLoS One 2010; 5:e9334.
10. Levy Y, Lacabaratz C, Weiss L, Viard JP, Goujard C, Lelievre JD, et al. Enhanced Tcell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009; 119:997-1007.
11. Angel JB, High K, Rhame F, Brand D, Whitmore JB, Agosti JM, et al. Phase III study ofgranulocyte-macrophage colony-stimulating factor in advanced HIV disease: effect on infections, CD4 cell counts and HIV suppression. Leukine/HIV Study Group. AIDS 2000; 14:387-395. (Pubitemid 30182435)
12. Napolitano LA, Schmidt D, Gotway MB, Ameli N, Filbert EL, Ng MM, et al. Growth hormone enhances thymic function in HIV- 1-infected adults. J Clin Invest 2008; 118:1085-1098. (Pubitemid 351364616)
13. Hansen BR, Kolte L, Haugaard SB, Dirksen C, Jensen FK, Ryder LP, et al. Improved thymic index, density and output in HIV-infected patients following low-dose growth hormone therapy: a placebo controlled study. AIDS 2009; 23:2123-2131.
14. Kilby JM, Bucy RP, Mildvan D, Fischl M, Santana-Bagur J, Lennox J, et al. A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). J Infect Dis 2006; 194:1672-1676. (Pubitemid 44901997)
15. Keh CE, Shen JM, Hahn B, Hallahan CW, Rehm CA, Thaker V, et al. Interruption ofantiretroviral therapy blunts but does not abrogate CD4 T-cell responses to interleukin-2 administration in HIV infected patients. AIDS 2006; 20:361-369.
16. Henry K, Katzenstein D, Cherng DW, Valdez H, Powderly W, Vargas MB, et al. A pilot study evaluating time to CD4 T-cell count < 350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: Results of ACTG A5102. J Acquir Immune Defic Syndr 2006; 42:140-148. (Pubitemid 43884707)
17. Porter BO, Anthony KB, Shen J, Hahn B, Keh CE, Maidarelli F, et al. Inferiority ofIL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial. AIDS 2009; 23:203-212.
18. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, Deeks SG. T cell activation isassociated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187:1534-1543. (Pubitemid 36578959)
19. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page- Shafer K, et al. Relationship between Tcell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197:126-133. (Pubitemid 351263476)
20. ANRS toxicity grading scale. In: http://www.anrs.fr/content/ download/2242/12805/file/ANRS-GradeEI-V12801-En-12008.pdf.
21. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb Mortal Wkly Rep 1992; 41:1-19.
22. Marchou B, Tangre P, Charreau I, Izopet J, Girard PM, May T, et al. Intermittent antiretroviral therapy inpatients with controlled HIV infection. AIDS 2007; 21:457-466.
23. El Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4+count-guided interruption ofantiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
24. Lewden C, Chene G, Morlat P, Raffi F, Dupon M, Dellamonica P, et al. HIV-infected adults with aCD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007; 46:72-77. (Pubitemid 47514615)
25. Zwahlen M, Harris R, May M, Hogg R, Costagliola D, de Wolf F, et al. Mortality ofHIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol 2009; 38:1624-1633.
26. Skiest DJ, Su Z, Havlir DV, Robertson KR, Coombs RW, Cain P, et al. Interruption ofantiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. J Infect Dis 2007; 195:1426-1436. (Pubitemid 46717460)
27. Thiébaut R, Pellegrin I, Chêne G, Viallard JF, Fleury H, Moreau JF, et al. Immunological markers after long-term treatment interruption in chronically HIV-1 infected patients with CD4 cell count above 400x10(6) cells/I. AIDS 2005; 19:53-61. (Pubitemid 40111018)
28. Bosch RJ, Pollard RB, Landay A, Aga E, Fox L, Mitsuyasu For The Aids Clinical Trials Group ATR. A randomized trial ofinterleukin- 2 during withdrawal of antiretroviral treatment. J Interferon Cytokine Res 2011; 31:481-483.
29. Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Sereti I, Sachau W, et al. Induction ofprolonged survival of CD4(+) T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest 2005; 115:2139-2148. (Pubitemid 41134155)
30. Fontas E, Kousignian I, Pradier C, Poizot-Martin I, Durier C, Weiss L, et al. IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy - results from the ANRS CO4 cohort. J Antimicrob Chemother 2010; 65:2215-2223.
31. Lane C. Baseline D-dimer Levels Identify a Subset of Patients at Higher Risk of Death following IL-2 Administration (abstract). 18th Conference on Retroviruses and Opportunistic Infections. Boston 2011. http://www. retroconference.org.
32. Sereti I, Imamichi H, Natarajan V, Imamichi T, Ramchandani MS, Badralmaa Y, et al. In vivo expansion ofCD4(+)CD45RO-CD25 (+) T cells expressing foxP3 in IL-2-treated HIV-infected patients. J Clin Invest 2005; 115:1839-1847. (Pubitemid 40979722)